Want to see AU:ATX full AI Analyst Report?

Amplia Therapeutics (ATX) Price & Analysis

23 Followers

ATX Stock Chart & Stats

AU$0.14

-AU$0.01(-7.14%)

At close: Jul 27 4:00 PM EDT

AU$0.14

-AU$0.01(-7.14%)

Day’s Range― - ―

52-Week RangeAU$0.10 - AU$0.28

Previous CloseN/A

Volume422.49K

Average Volume (3M)525.22K

Market Cap

AU$66.73M

Enterprise ValueAU$93.06

Total Cash (Recent Filing)AU$27.85M

Total Debt (Recent Filing)AU$341.11K

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Nov 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding513,312,000

10 Day Avg. Volume444,673

30 Day Avg. Volume525,217

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)2.80

Price to Sales (P/S)0.00

P/FCF Ratio-12.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.42

Price Target Upside200.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA sizable equity cushion versus assets provides lasting financial flexibility for a pre-revenue biotech. This reduces near-term refinancing pressure, supports continued R&D spending and trial progression over months, and gives management time to reach value-driving clinical inflection points.

Focused Oncology PipelineA clear, focused R&D strategy centered on FAK inhibition with a lead asset targeting high-unmet-need solid tumors concentrates resources and expertise. This specialization can improve development efficiency, partner attractiveness, and the probability of value capture if clinical results progress over the medium term.

Prior Strong Gross MarginsHistorically strong gross margins indicate that if the company commercializes a therapy, product economics could be favorable. Durable gross-profit potential supports long-term margin sustainability and scalability, assuming successful clinical development and controlled commercial costs.

Bears Say

Zero Recent RevenueDropping to zero revenue and widening losses is a material structural weakness: without product sales the firm must rely on financing, which can dilute shareholders and constrain strategic optionality. Continued negative results lengthen time to self-sustaining operations.

Worsening Cash BurnConsistent negative operating and free cash flow with increased burn in the latest year erodes runway and raises fundraising frequency. This structural cash dependency heightens dilution and execution risk, especially for costly clinical programs requiring multi-period funding.

Negative Returns On EquityDespite a strong equity cushion, sustained negative ROE shows the capital base isn't producing returns. Over months this can weaken investor confidence, limit access to favorable capital, and pressure management to raise funds or cut programs if clinical progress does not de-risk assets.

Amplia Therapeutics News

Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push

Amplia Therapeutics ( ($AU:ATX) ) has issued an announcement. Amplia Therapeutics has released a presentation for the Bioshares...

3d ago

Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data

Amplia Therapeutics ( ($AU:ATX) ) has provided an announcement. Amplia Therapeutics has highlighted new preclinical research on its...

9d ago

Amplia advances FAK inhibitor program with new trials, patent gains and board refresh

An update from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia reported mature data from its ACCENT...

11d ago

Amplia Therapeutics Issues New Employee Incentive Options

Amplia Therapeutics ( ($AU:ATX) ) has issued an update. Amplia Therapeutics has notified the ASX of the issue...

25d ago

Amplia Therapeutics Issues New Employee Incentive Options

Amplia Therapeutics ( ($AU:ATX) ) has provided an update. Amplia Therapeutics has notified the market of the issue...

25d ago

Amplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics Limited has filed an Initial Director’s Interest...

1M ago

Amplia strengthens board with industry deal-maker Brett Carter

Amplia Therapeutics ( ($AU:ATX) ) has issued an announcement. Amplia Therapeutics has appointed biopharmaceutical executive Brett Carter as...

1M ago

Amplia Therapeutics Sets August AGM Amid Progress in FAK Cancer Trials

Amplia Therapeutics ( ($AU:ATX) ) has shared an update. Amplia Therapeutics has scheduled its Annual General Meeting for...

1M ago

Amplia Therapeutics reshapes board leadership as clinical momentum builds

Amplia Therapeutics ( ($AU:ATX) ) has provided an update. Amplia Therapeutics has announced a planned change in board...

1M ago

Amplia lodges updated ASX corporate governance statement for 2026

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics has lodged its updated corporate governance statement...

2M ago

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

RADX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

ATX FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?

Amplia Therapeutics Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.

What is Amplia Therapeutics Ltd.’s market cap?

Amplia Therapeutics Ltd.’s market cap is AU$66.73M.

When is Amplia Therapeutics Ltd.’s upcoming earnings report date?

Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 109 days.

How were Amplia Therapeutics Ltd.’s earnings last quarter?

Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Amplia Therapeutics Ltd. overvalued?

According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amplia Therapeutics Ltd. pay dividends?

Amplia Therapeutics Ltd. does not currently pay dividends.

What is Amplia Therapeutics Ltd.’s EPS estimate?

Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amplia Therapeutics Ltd. have?

Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.

What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?

Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Amplia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

98.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amplia Therapeutics Ltd.

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Amplia Therapeutics (ATX) Earnings & Revenues

Historic Earnings Reports

ATX Stock 12 Month Forecast

Average Price Target

AU$0.42

▲(200.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.13,0.1523076923076923,0.17461538461538462,0.19692307692307692,0.21923076923076923,0.24153846153846154,0.26384615384615384,0.28615384615384615,0.30846153846153845,0.33076923076923076,0.35307692307692307,0.37538461538461537,0.3976923076923077,{"y":0.42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.13,0.1523076923076923,0.17461538461538462,0.19692307692307692,0.21923076923076923,0.24153846153846154,0.26384615384615384,0.28615384615384615,0.30846153846153845,0.33076923076923076,0.35307692307692307,0.37538461538461537,0.3976923076923077,{"y":0.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.13,0.1523076923076923,0.17461538461538462,0.19692307692307692,0.21923076923076923,0.24153846153846154,0.26384615384615384,0.28615384615384615,0.30846153846153845,0.33076923076923076,0.35307692307692307,0.37538461538461537,0.3976923076923077,{"y":0.42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.165,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.17,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.12,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.265,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >